VTI - Vanguard Total Stock Market Index Fund
| Previous Close | 137.50 |
| Open | 137.78 |
| Bid | 134.00 x 200 |
| Ask | 140.00 x 500 |
| Day's Range | 136.81 - 138.16 |
| 52 Week Range | 120.85 - 146.87 |
| Volume | 2,034,128 |
| Avg. Volume | 3,412,901 |
| Net Assets | 672.38B |
| NAV | 135.69 |
| PE Ratio (TTM) | N/A |
| Yield | 1.74% |
| YTD Return | -0.70% |
| Beta (3y) | 1.00 |
| Expense Ratio (net) | 0.04% |
| Inception Date | 2001-05-24 |
- Morningstar•4 days ago
3 ETF Retirement Saver Portfolios for Taxable Accounts
Composed of broad-market equity ETFs and smaller allocations to municipal bonds, these portfolios are designed for retirement savers' taxable accounts.
- Forbes•21 days ago
Investment Strategies To Improve On Passive U.S. Indexing
For many, passive indexing against a robust U.S. index is a sound strategy. But academic research suggests there may be a view ways to improve risk-adjusted returns beyond this. We explore implementing these strategies with popular ETFs.
- Investopedia•21 days ago
Top 3 ETFs for Long-Term Investors as of March 2018
Long-term investors may find these buy-and-hold ETFs very appealing.
- Market Realist•22 days ago
Equity ETFs Witnessed Net Outflows Last Week
Financials Had Solid Gains on March 26–29
- Forbes•last month
4 Other Ways To Time The Market
Market timing is generally agreed to be extremely challenging. Yet seasonal factors do persist in the market over time and could offer you a slight edge when buying or selling.
- Investopedia•2 months ago
Top 3 ETFs for Long-Term Investors as of February 2018
Long-term investors may find these buy-and-hold ETFs very appealing.
- Forbes•2 months ago
Live Well While The Market Tanks
A spending formula to protect you in retirement from panic and from penury.
Market Realist•2 months agoA Deep Look at Globus Medical’s Financial Performance
Here's What's in Store for Globus Medical in 2018
Market Realist•3 months agoHow Did Orkambi Perform in 4Q17 and 2017?
How Is Vertex Pharmaceuticals Positioned after 4Q17? In 4Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of $365 million, which reflected ~32% growth on a year-over-year (or YoY) basis and 9% growth on a quarter-over-quarter (or QoQ) basis. In fiscal 2017, Orkambi generated revenues of $1.3 billion, a ~35% increase on a YoY basis.
Market Realist•3 months agoBiogen: How It Performed in 4Q17
Biogen: How It Performed in 4Q17Biogen’s revenue trends
Market Realist•3 months agoAbbott Laboratories on the Street: Analyst Recommendations after the 4Q17 Results
What's Next for Abbott Laboratories after a Stellar 2017?
- Market Realist•3 months ago
What Else Could Drive Gilead’s Long-Term Growth?
Where's Gilead Sciences Now? Key January Updates
- Market Realist•3 months ago
What Does Mexico’s Manufacturing PMI Indicate?
A Look at Emerging Market December PMI Reports
- Morningstar•3 months ago
An Aggressive ETF Bucket Portfolio for Retirement
This ETF-oriented portfolio is ideal for retirees with long time horizons.
- Morningstar•3 months ago
A Conservative ETF Bucket Portfolio for Retirement
This ETF-oriented portfolio is ideal for retirees with shorter time horizons.
- Morningstar•3 months ago
A Moderate ETF Bucket Portfolio for Retirement
This portfolio is geared toward retirees with roughly 20-year time horizons.
- Morningstar•3 months ago
A Conservative Retirement Saver Portfolio for ETF Investors
For a pre-retiree, our portfolio includes a larger--and better diversified--stake in bonds.
- Market Realist•3 months ago
How Juno Therapeutics’ Cellular Immunotherapy Portfolio Could Help Celgene
Celgene to Acquire Juno Therapeutics: A Deeper Read
- InvestorPlace•3 months ago
Why Warren Buffett Is Spot-On With His Vanguard Fund Advice
Warren Buffett is arguably the most famous investor of our time — likely all-time. Some others, like Carl Icahn, Jim Chanos and George Soros are well-known and for good reason. Humble about himself and with his wallet, Buffett has pretty sound (and simple) advice for retail investors, specifically when it comes to Vanguard funds.
Market Realist•3 months agoNektar’s Deals: AstraZeneca, Amgen, Bayer
A Look at Nektar Therapeutics' Revenue Drivers in 2018
- Market Realist•3 months ago
Intuitive Surgical’s Da Vinci Procedure Could Boost 2017 Results
According to Intuitive Surgical’s (ISRG) preliminary 4Q17 and 2017 results posted by the company on January 10, 2018, it expects to post da Vinci procedure growth of 17% in 4Q17 and 16% for fiscal 2017 on a YoY (year-over-year) basis. About 877,000 procedures are estimated to be performed with da Vinci surgical systems around the world in fiscal 2017. The US general surgery and global urologic procedure growths continue to be the major drivers behind the da Vinci procedure growth.
- Market Realist•3 months ago
The Other Side of Legalizing Recreational Marijuana
While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse. Some groups are concerned that legalizing marijuana would make it even easier for young people to access the drug.
- Market Realist•3 months ago
The Marijuana Ecosystem’s Potential Business Opportunities
In the previous part of this series, we discussed Constellation Brands’ (STZ) investment in the marijuana industry. Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave. Below, we discuss some of the business opportunities that could develop as a result of marijuana legalization.
- Market Realist•3 months ago
Will Abbott’s 4Q17 Sales Results Exceed Analysts’ Expectations?
What to Expect from Abbott Laboratories' 4Q17 Results
